Browsing Tag
LGMD2I
1 post
The rare disease opportunity behind BridgeBio Pharma’s BBP-418 breakthrough (NASDAQ: BBIO)
BridgeBio Pharma advances BBP-418 after Phase 3 muscular dystrophy results. Could the therapy unlock a major rare disease opportunity? Read the full analysis.